Yükleniyor... / Loading...
This observational study examines the biological features of tumors, using RNA sequencing (RNAseq), in patients with advanced non-small cell lung cancer (NSCLC) that carries an ALK gene rearrangement. It is enrolling patients aged 18 and older who are being treated with a next-generation ALK inhibitor in the first line and are part of the EXPLORE ALK study. This study has no assigned phase and is still recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+6
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent * ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods * Patient included in the EXPLORE ALK study * Age \> or = 18 years * Patient treated with first-line new generation ALKi * Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available * Patient enrolled in the french National Health Insurance program or with a third- party payer Exclusion Criteria: * Patients who do not wish to participate in Bioexalk * Patients under guardianship